{
    "organizations": [],
    "uuid": "66fd937db519b24c6fbc863fb6a70662e313940a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-granted-alnylams-request-for-p/brief-fda-granted-alnylams-request-for-priority-review-idUSASB0C3MO",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Granted Alnylam's Request For Priority Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS\n* ALNYLAM PHARMACEUTICALS INC - FDA ALSO GRANTED COMPANY‘S REQUEST FOR PRIORITY REVIEW AND HAS SET AN ACTION DATE OF AUGUST 11, 2018\n* ALNYLAM PHARMACEUTICALS INC - ‍AT THIS TIME, FDA IS NOT PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T05:21:00.000+02:00",
    "crawled": "2018-02-02T12:43:08.035+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "announces",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "nda",
        "priority",
        "review",
        "status",
        "patisiran",
        "investigational",
        "rnai",
        "therapeutic",
        "treatment",
        "hereditary",
        "attr",
        "hattr",
        "amyloidosis",
        "alnylam",
        "pharmaceutical",
        "inc",
        "fda",
        "also",
        "granted",
        "company",
        "request",
        "priority",
        "review",
        "set",
        "action",
        "date",
        "august",
        "alnylam",
        "pharmaceutical",
        "inc",
        "time",
        "fda",
        "planning",
        "hold",
        "advisory",
        "committee",
        "meeting",
        "discus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}